MMP9 and central nervous system neoplasm: Our data indicate that patients suffering from malignant, but not benign brain tumours can be distinguished from CTRL patients based on the MMP-9 level of serum sEVs, and that the MMP-9 level of serum sEVs differs between CNS tumour types, showing a positive correlation with tumour aggressiveness.